Related Experiment Video
Updated: Mar 1, 2026
05:26
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
9.7K
Optimal Antiplatelet Therapy in ST-Segment Elevation Myocardial Infarction.
1Department of Cardiology, The Mount Sinai Hospital, One Gustave L. Levy Place, New York, NY 10029-6574, USA.
Interventional Cardiology Clinics
|June 6, 2017
Summary
Antiplatelet therapy is crucial for treating myocardial infarction (MI). This review focuses on the current use of antiplatelet agents in ST-segment elevation MI, a significant advancement in cardiovascular disease treatment.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardiovascular disease is a leading global cause of mortality.
- Decreased myocardial infarction (MI) case-fatality rates in the US are attributed to improved acute MI treatments and secondary prevention.
- Antiplatelet therapy is fundamental in managing MI.
Purpose of the Study:
- To review the current landscape of antiplatelet therapy.
- To specifically address its application in ST-segment elevation myocardial infarction (STEMI).
Main Methods:
- Literature review of current antiplatelet therapies.
- Focus on evidence pertaining to STEMI management.
Main Results:
- Antiplatelet therapy remains a cornerstone in MI treatment.
- Advances in secondary prevention have significantly reduced MI mortality.
- Current strategies for STEMI involve specific antiplatelet regimens.
Conclusions:
- Antiplatelet therapy is essential for STEMI patients.
- Ongoing research and clinical practice evolve antiplatelet strategies for better outcomes in MI.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:28Acute Coronary Syndrome IV: Interprofessional Care
347
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
347
01:30Acute Coronary Syndrome I: Introduction
1.3K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.3K
01:27Peripheral Artery Disease III: Interprofessional Care
443
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
443
01:27Coronary Artery Disease V: Interprofessional Care
346
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
346
01:26Angina IV: Management
366
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
366